Advertisement

Topics

Clinical Trials About "Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes" RSS

21:11 EDT 17th August 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes" on BioPortfolio

We have published hundreds of Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes news stories on BioPortfolio along with dozens of Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Clinical Trials and PubMed Articles about Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Companies in our database. You can also find out about relevant Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Drugs and Medications on this site too.

Showing "Safety Tolerability Pioglitazone Azilsartan Subjects With Type Diabetes" Clinical Trials 1–25 of 36,000+

Extremely Relevant

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.


Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

The purpose of this study is to determine the safety and tolerability of pioglitazone-azilsartan, once daily (QD), in patients with type 2 diabetes mellitus.

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.


Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

Safety and Efficacy of Azilsartan Medoxomil in Subjects With Mild to Moderate Hypertension

The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.

Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

The current study investigates Welchol as add-on therapy to pioglitazone to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if Welchol add-on to pioglitazone therapy for Type 2 Diabetes Mellitus will be safe, well tolerated, and efficacious.

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

The purpose of this study is to determine the safety and efficacy of azilsartan, once daily (QD), in subjects with essential hypertension.

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in subjects with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.

The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on lipid measures in type 2 diabetes subjects after eating.

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects Treated with Insulin.

Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

This study is being done to determine if pioglitazone (Actos) is helpful to patients with type 2 diabetes and could possibly prevent harmful consequences of cardiovascular disease in diabetic patients.

Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes

The purpose of this study is to determine the efficacy of pioglitazone and metformin combination therapy, once daily (QD), on glycosylated hemoglobin in adults with type 2 diabetes.

Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.

The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

This multi-center, randomized, double-blind, active controlled, parallel-group s tudy in type 2 diabetes patients with moderate renal impairment will evaluate th e effect on renal function and the safety and tolerability of aleglitazar compar ed with pioglitazone. Patients will be randomized to receive either 150 mcg aleg litazar or 45 mg pioglitazone as daily oral doses. In addition, a diet and exerc ise plan will also be implemented during the anticipated time on study treatm...

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied.

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg in patients with type 2 diabetes mellitus with insufficient glycaemic control.

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in subjects with moderate to severe hypertension.

Initial Combination With Pioglitazone Study

A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30 mg, or 45 mg, administered orally once daily), and linagliptin (5 mg, administered orally once daily). In addition, durability of treatment effect and safety under chronic treatment conditions will be investigated.

Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes

The purpose of this trial is to study the efficacy and safety of pioglitazone added to combination therapy of sulfonylurea plus metformin with placebo in patients with type 2 diabetes.


More From BioPortfolio on "Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement